Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA™ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis July 9, 2019 - NASDAQ Companies 0 » View More News for July 09, 2019
